Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

AIMS: Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of dapagliflozin, which lowers systolic blood pressure (SBP),according to baseline SBP in Dapagliflozin and Prev...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur Heart J
Autori principali: Serenelli, Matteo, Böhm, Michael, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Anand, Inder S, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Diez, Mirta, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E A, Verma, Subodh, Docherty, Kieran F, Jhund, Pardeep S, McMurray, John J V
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550197/
https://ncbi.nlm.nih.gov/pubmed/32820334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa496
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi